Valens: Canaccord Lowers Price Target To $3.75

Earlier this month, The Valens Company (TSX: VLNS) reported their fiscal third-quarter financial results. The company reported net revenue of $20.99 million, up from the $18.76 million reported last quarter. Gross margins were 26.8% for the quarter compared to 22% last quarter, while adjusted EBITDA came in lower than last quarter at negative $6.18 million. The company reported a net loss of $12.8 million. Valens saw its SKU count go from 75 at the end of the first fiscal quarter to now 181 at the end of this quarter.

The Valens Company currently has 9 analysts covering the stock with an average 12-month price target of C$3.92, or 89% upside. Out of the 9 analysts, 1 has a strong buy rating, 7 have buys and 1 analyst has a hold rating. The street high sits at C$5.25 from Stifel-GMP, while the lowest comes in at C$2.50.

In a note, Canaccord Genuity lowered their price target to C$3.75 from $4.25 and speculative buy rating saying that after their first run-through the company is now focusing on margins. For the quarter, Canaccord forecasted revenue to be C$22.5 million.

Canaccord notes that this quarter included partial sales from Green Roads which accounted for C$4.7 million, so if you would back that out then sales would have declined by 12%. They write that this decline would be attributed to the company “transitioning away from smaller, underperforming B2B partners in favour of building deeper relationships with larger LPs.”

Onto gross margins, the company saw a 4.8% increase in gross margins, which can be partially attributed to the Green Roads inclusion. Canaccord writes, “Having now achieved critical mass for its SKU listings, VLNS plans to shift focus to driving margin expansion through automation, volume growth, and operational efficiencies.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Cowen & Co Issues US Cannabis Update, Remains Bullish on Green Thumb, Cresco, Curaleaf

On the first of the month, Cowen and Co sent out an industry update specifically...

Sunday, September 6, 2020, 01:37:00 PM

Galaxy Digital: BMO Initiates With $43 Price Target

Galaxy Digital Holdings (TSX: GLXY), a hodgepodge of different crypto businesses under one company, just...

Wednesday, November 3, 2021, 04:08:00 PM

Canaccord: 2020 To Be Transition Year For Medipharm Labs

Last week, Medipharm Labs (TSX: LABS) reported their second-quarter earnings. Revenue came in at $13.9...

Saturday, August 22, 2020, 01:38:00 PM

Greenlane: Canaccord’s Take On The KushCo Merger

On March 31st, Greenlane Holdings (NASDAQ: GNLN) announced their fourth quarter and full-year financial results....

Tuesday, April 6, 2021, 11:51:00 AM

Aurora: Canaccord Raises Price Target To $14.00 On Back Of Earnings

Last night, Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported its second quarter 2020 earnings. They...

Friday, February 12, 2021, 04:02:00 PM